Insulet Corporation (PODD)
Here's Why Insulet (PODD) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet (PODD) Just Overtook the 50-Day Moving Average
Insulet (PODD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PODD broke through the 50-day moving average, which suggests a short-term bullish trend.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript
Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)
Insulet Corporation has rebounded with strong revenue and profit growth, now approaching the lower end of fair value. PODD delivered Q1 2026 revenue of $761.7M (+33.9% YoY), with net income and operating cash flow nearly doubling. Management forecasts 21–23% revenue growth in 2026, driven by Omnipod 5 adoption and international expansion, despite competitive threats from weight-loss drugs.
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock?
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PODD Stock: What a Hold Rating Says at a $163 Target
Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.
PODD and Omnipod 5: What's Driving Insulet's 2026 Growth
Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.
Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insulet: An Opportune Time To Get Involved
Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Insulet raised full-year guidance to 21-23% sales growth and expects adjusted earnings to exceed $6.25 per share, reflecting strong Omnipod 5 adoption. Valuation has rebounded, with shares trading at 70x forward earnings and 10x sales, leaving little room for error amid decelerating growth.
